Notice of Decision of Patent in South Korea

RNS Number : 9915K

Eden Research plc

01 July 2014

 



Eden Research Plc

("Eden" or "Company")

Notice of Decision of Patent Registration in South Korea

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that it has received a Notice of Decision of Patent Registration from the Korean Patent Office for its patent covering the use of its GO-E Inside™ encapsulation technology in the treatment of mites.

The patent covers the Company's core technology, specifically "A method of killing mites which infest plants, said method comprising the step of administering to said mites in an effective dose a composition comprising a hollow glucan particle or cell wall particle encapsulating a terpene component, wherein the terpene component comprises citral alone or a combination of eugenol, thymol and citral."

Clive Newitt, Managing Director of Eden comments: "The patent coverage in South Korea follows the Mexican patent that was awarded back in May, and is another extension of our valuable portfolio of patent protection globally. We are delighted to move into South Korea as it is a large market for us to penetrate with a number of interesting opportunities particular in the area of fungicides for agricultural use, which is worth over US $200m in South Korea alone focussing on produce such as rice, and key fruit and vegetables. This patent brings the total number of granted patents for Eden to 46."

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	www.wh-ireland.co.uk
John Wakefield	Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCFMMRTMBJJBTI